1. Introduction {#sec1}
===============

Currently in the U.S. population, 13% or 30 million adults have an alcohol use disorder (AUD) ([@bib77]), which is primarily characterized by a loss of control over drinking, preoccupation with drinking, continued use despite negative consequences (e.g., health, job function, interpersonal relationships), tolerance, and withdrawal. Alcohol consumption is the third leading cause of preventable morbidity and mortality in the U.S. ([@bib146]), and losses to the economy exceed \$249 billion per year ([@bib185]). Alcohol causes the most harm to self and others when considered in the context of all other substances (including tobacco and opioids) ([@bib159]) and the U.S. exceeds global per capita alcohol consumption by 50%, potentially impacting the prevalence of AUD in the U.S. ([@bib193]; [@bib130]).

Historically, rates of AUD have been greater in men when compared to women, however, this gap is closing ([@bib227]). Over the past ten years, rates of AUDs have increased in women by 84%, relative to a 35% increase in men ([@bib77]), such that currently the weighted rate of AUDs among adults in the United States is 9.0% in women and 16.7% in men ([@bib77]). Similarly, there have been substantial increases in the prevalence of alcohol use and binge drinking in women, but not men, assessed over the past 16 years in several national data sources ([@bib82]). Factors associated with increasing rates of AUD in women include drinking to regulate negative affect, the experience of negative emotions or being in a negative emotional state, and stress, as well as greater sensitivity to alcohol-induced neurodegeneration ([@bib3]; [@bib157]; [@bib110]; [@bib192]). While stress and negative affect are strongly associated with all phases of alcohol addiction, including drinking initiation, maintenance, and relapse, for both women and men, they play an especially critical role for women ([@bib110]; [@bib106]; [@bib220]).

This substantive increase in female alcohol consumption is especially alarming as women have exacerbated alcohol-related health consequences when compared to men. While drinking is strongly associated with significant health risks in both sexes, women with AUDs have a higher risk of developing alcohol-related liver injury, including liver cirrhosis, and hepatitis compared to men ([@bib151]; [@bib5]; [@bib208]), even though women may consume less alcohol and have a shorter duration of use ([@bib179]). Alcohol use increases the risk of cancers of the mouth, esophagus, pharynx, larynx, liver, and breast, and women are at greater risk of alcohol-related cancer than men ([@bib151]; [@bib97]). Additionally, women are more vulnerable to alcohol-related cardiovascular conditions than men ([@bib3]; [@bib151]). While there is some evidence that low to moderate alcohol consumption protects against ischemic stroke, among women consuming three or more drinks per day there is an increased risk of stroke relative to men ([@bib166]).

In addition to experiencing greater relative risk than men for the most common and serious alcohol-related diseases, women also face other sex-dependent health consequences from drinking. Excessive alcohol consumption is associated with menstrual irregularity and altered hormone levels during menstrual cycle phases ([@bib131]; [@bib132]), including increases in endogenous estradiol ([@bib61]) and temporary increases in testosterone levels ([@bib132]; [@bib61]). These hormonal increases have been associated with incidence of female-related health problems, including cancers (e.g., breast) and poor reproductive health. There is a clear linear relationship between increased alcohol consumption and incidence of breast cancer in women ([@bib42]), with a 22% excess risk that rises about 10% for each 10 g of alcohol consumed per day ([@bib104]). Pregnancy- and perinatal-related consequences of drinking include infertility and spontaneous abortion ([@bib9]), as well as significant cognitive, psychological, and behavioral problems in offspring, including fetal alcohol syndrome ([@bib151]). Alcohol use is also associated with increased risk of physical and sexual assaults among women, with approximately one half of cases involving alcohol consumption by either the victim, perpetrator, or both ([@bib16]). Despite the significant increase in alcohol consumption among women and the associated health risks, few attempts have been made to develop treatments to address sex-dependent factors associated with problematic alcohol consumption in women versus men. This highlights the urgent need to include sex as a biological variable (SABV) in future alcohol-related research.

Sex differences exist at all levels of biological organization including brain anatomy, neurochemistry, connectivity, and function ([@bib48]; [@bib122]; [@bib45]; [@bib143]), with relevance for understanding sex-based differences in addiction ([@bib192]). However, the consideration of sex in preclinical and human research has historically been inadequate. For example, an examination of sex bias in preclinical biomedical research found male bias in eight fields, with neuroscience demonstrating the largest bias ([@bib24]). Regarding addiction, male participants are included at higher rates than females, and many studies that include both sexes do not analyze results by sex. In an effort to combat male bias, the National Institutes of Health (NIH) required the inclusion of women in clinical research (1993) ([@bib46]) and, more recently, SABV in basic and preclinical research ([@bib46]). The inclusion of SABV is a key element to increase scientific rigor and reproducible findings, in order to guide clinical studies and practice. As advances are made in the biomedical field to include SABV in preclinical and clinical research, it is critical to consider the role of sex in mechanisms underlying disease, including AUD ([@bib85]), and translate these findings towards effective treatment for both women and men.

The purpose of the present narrative review is to highlight what is known about sex differences in the relationship between stress (see [Table 1](#tbl1){ref-type="table"} for a list of stress paradigms in preclinical and clinical research included in this review) and drinking. An exhaustive search was conducted to identify relevant manuscripts related to sex, stress, and alcohol use in the preclinical and human literature (see supplementary materials for search details). Specifically, the critical role stress reactivity and negative affect play in initiating and maintaining alcohol use in women will be addressed, including how sex differences emerge in neuroadaptations of stress pathophysiology with continued alcohol use. Furthermore, this review aims to highlight the state of the field, identify gaps in our knowledge, and suggest ways to translate this knowledge to effectively target sex-dependent mechanisms to improve AUD treatment.Table 1Stress paradigms in preclinical and clinical research included in the present review.Table 1ParadigmIndicationReference in manuscriptPreclinical Learned helplessnessDepression[@bib218] SDPS[a](#tbl1fna){ref-type="table-fn"}Depression[@bib180] Predator odorPsychological stress/PTSD[b](#tbl1fnb){ref-type="table-fn"}[@bib50] Tail suspensionPsychological stress/acute stress[@bib50] RestraintPhysical stress/acute stress[@bib50] Foot shockPhysical stress/acute stress[@bib50]; [@bib117]; [@bib235] Tail pinchPhysical stress/acute stress[@bib50] Noise stressMild stress exposure/acute stress[@bib18] Yohimbine[e](#tbl1fne){ref-type="table-fn"}Pharmacologic stress/acute stress[@bib30]; [@bib117]; [@bib235]Clinical CRF[c](#tbl1fnc){ref-type="table-fn"}/cortisol administrationIncrease pituitary-adrenal axis response[@bib90] Citalopram stimulation testAssess neuroendocrine reaction[@bib14] Combined dexamethasone/CRF[c](#tbl1fnc){ref-type="table-fn"} testAssess glucocorticoid feedback loop[@bib189]; [@bib14] CosyntropinAssess adrenocortical response[@bib2] Combined Cosyntropin/dexamethasoneAssess neuroendocrine feedback[@bib2] Trier Social Stress TestPsychological stress[@bib113] Imagery ScriptsPsychological stress[@bib41]; [@bib138]; [@bib190]; [@bib113] Emotionally arousing filmsArouse negative emotions[@bib38] IAPS[d](#tbl1fnd){ref-type="table-fn"}Induce highly charged emotions[@bib71] Public speaking challengePsychological stress[@bib25]; [@bib128]; [@bib204] Mental arithmetic taskPsychological stress[@bib26]; [@bib25]; [@bib62]; [@bib204][^2][^3][^4][^5][^6]

2. Do stress and negative affect drive initiation and maintenance of alcohol use for women? {#sec2}
===========================================================================================

2.1. Drinking for negative affect regulation in adolescence {#sec2.1}
-----------------------------------------------------------

Negative affect is strongly associated with the onset of drinking and subsequent dependence among adolescents in both preclinical models of anxiety-like behavior and clinical depressive and anxiety symptomatology ([@bib98]; [@bib87]). For example, a clinical study of older adolescents (ages 15--18 years old) demonstrated that the severity of depressive symptoms, as measured by Hopkins Symptom Checklist-25, was associated with earlier onset of alcohol use, frequent alcohol consumption, and intoxication in both boys and girls ([@bib98]). However, the association between early drinking onset and anxiety/depressive symptoms was stronger in girls ([@bib98]). Initial depressive symptoms during early adolescence in girls were also associated with increased problematic alcohol use later in adolescence ([@bib57]). This is consistent with findings in the preclinical literature showing that female adolescent rodents with higher social anxiety-like behavior exhibit increased alcohol drinking compared to male adolescent rodents ([@bib217]). During mid-adolescence, there is a decline in sensation-seeking as well as more control of impulsivity among girls when compared to adolescent boys ([@bib195]). Overall, given the association between negative affect and onset of alcohol use, these differences in developmental trajectories between boys and girls may contribute to adolescent girls being more apt to drink to cope with negative affect.

2.2. Role of early life stress and childhood maltreatment {#sec2.2}
---------------------------------------------------------

Both preclinical and clinical research have demonstrated that exposure to early life stress has long-term effects on stress reactivity and alcohol use ([@bib37]; [@bib206]; [@bib89]). Repeated exposure to early life stressors, prior to 17 years of age, is associated with an increased risk for subsequent problematic alcohol use among young adults (18--25 years of age) ([@bib194]). Recent findings also suggest that women endorsing a history of maltreatment before age 18 may display more vulnerability to negative alcohol outcomes, including earlier drinking onset and increased rates of AUDs ([@bib64]; [@bib66]). Specifically, sexual abuse, emotional neglect, and emotional abuse were associated with increased rates of AUDs in women compared to men ([@bib66]; [@bib188]).

Of note, data from a national survey of cigarette smokers suggest that approximately 41% of women and 49% of men endorse physical or emotional maltreatment prior to age 18, while approximately 30% of women and 18% of men endorse serious psychological distress as children ([@bib199]). Additional epidemiological data demonstrated that 10.8% of women and 6.6% of men who endorse maltreatment during childhood later met criteria for a lifetime alcohol dependence diagnosis ([@bib160]). This suggests that while base rates should be considered when investigating the underlying effects of childhood maltreatment on drinking, women have unique mechanisms contributing to higher rates of subsequent alcohol dependence. Preclinical research also supports the association between early life stress and subsequent alcohol use; corticosterone exposure during adolescence (aged 27--28 days) increased alcohol drinking and seeking in female rodents to a greater degree than males ([@bib30]), suggesting an effect of early stress on alcohol-motivated behavior.

2.3. Sex differences in brain morphology in adolescence {#sec2.3}
-------------------------------------------------------

Early life stress is associated with long-lasting alterations in the mesolimbic dopamine (DA) pathway, changes in neurotransmitter systems implicated in the stress response (e.g., norepinephrine \[NE\], corticotropin-releasing factor \[CRF\]), and changes in brain morphometry, including decreased volume in the corpus callosum, anterior cingulate cortex and amygdala, as well as reduction in volume and synaptic density in the hippocampus (for review see ([@bib58]; [@bib75])). It has been postulated that the strong relationship between negative affect and the initiation of alcohol use in adolescent girls ([@bib57]) may be related to the effect of early life stress on corticolimbic function, which is less responsive to alcohol in women, and thus increases vulnerability for alcohol use and misuse ([@bib110]).

There is emerging evidence that the brains of women and men further differentiate in adolescence. In youth, girls tend to display more interhemispheric communication than boys, possibly facilitating connectivity between subcortical areas related to analytical and intuitive processing, whereas boys display more intrahemispheric communication than girls ([@bib110]; [@bib96]). While the impact of these differences on behavior is not yet clear, it is likely that these differences in corticolimbic function during adolescence contribute to the observation that girls are more likely to drink to regulate negative affect. These differences in brain morphology also continue to emerge in adulthood, such that adult women have more gray matter in the medial prefrontal cortex (PFC), an area important for regulating executive function, while males have more gray matter in the anterior cingulate cortex, an area involved in hedonic and impulsive activity ([@bib110]; [@bib182]). It is likely that these sex differences in human brain structure alter brain function leading to sex differences in the cycle of AUD, including maintenance and relapse ([@bib109]).

2.4. Relationship between drinking and negative affect into adulthood {#sec2.4}
---------------------------------------------------------------------

The relationship between stress, negative affect and alcohol use continues into adulthood, with particularly salient consequences for women ([@bib35]). For example, women endorsing two or more past year stressful life events were 4 times more likely to have a new onset AUD, whereas men with two or more past year stressful life events were 2.5 times more likely to have a new onset AUD ([@bib220]). Additionally, women are more likely to relapse in response to stress ([@bib23]), whereas acute stress has been generally shown to have minimal impact on subjective responses to alcohol among men ([@bib43]). Furthermore, women have sensitized responses to stress during periods of alcohol withdrawal ([@bib192]; [@bib23]). These findings are consistent with the preclinical literature demonstrating that female rodents consume more alcohol in an animal model of depression ([@bib218]) and are more reactive to stress-induced relapse ([@bib30]).

Psychiatric comorbidities such as depression, anxiety disorders, and posttraumatic stress disorder (PTSD) are strongly associated with problematic drinking, and to a higher degree in women compared to men. There is a stronger relationship between negative affect and alcohol-related measures, including alcohol consumption, craving, binge drinking, problematic use, and dependence in women than men ([@bib34]; [@bib103]; [@bib44]; [@bib12], [@bib13]). For example, data from NESARC-III suggests there are higher rates of co-morbidity between AUD and major depression in women than in men (24% vs. 13%; unpublished data). Social drinking women report higher levels of sadness and anxiety following stress-induction as compared to men, and women with alcohol dependence report higher levels of depression and anxiety than their male counterparts, indicating that women are particularly vulnerable to emotional stress ([@bib41]; [@bib105]). This has been shown to affect alcohol consumption, as women diagnosed with alcohol dependence report a higher frequency of heavy alcohol consumption during negative emotional states ([@bib1]). Additionally, rumination is a prospective predictor of alcohol-related problems among women but not men ([@bib156]). When compared to men, women report drinking more in response to unpleasant emotions and interpersonal conflict, and this relationship is mediated by depressive symptom severity ([@bib115]).

Unsurprisingly, the relationship between stress, negative affect, and alcohol use is also observed when exploring PTSD symptomatology and comorbid alcohol use (PTSD-AUD). Women are more likely than their male counterparts to be diagnosed with PTSD-AUD (14% vs. 6%) and women are also more likely to endorse that PTSD preceded AUD ([@bib203]). Women also endorse greater intensity and frequency of avoiding trauma-related cognitions/feelings and social impairment compared to males, and thus may use alcohol and drugs to alleviate PTSD-related negative affect ([@bib203]; [@bib91]). Overall, both women and men with PTSD-AUD report drinking to cope; however, men display greater drinking for enhancement of positive emotions, while alcohol consumption is related to drinking to cope among women ([@bib118]). Preclinical research supports such conclusions as female rodents are more likely to increase alcohol intake in an animal model of PTSD compared to males ([@bib50]).

As reviewed in the prior section, sex differences regarding alcohol onset and maintenance begin to emerge in early adolescence, with exposure to early life stress, developmental changes and emerging differences in brain morphology underlying the role of stress and negative affect in alcohol use, particularly for women. The relationship between stress, negative affect, and alcohol use continues into adulthood with increased vulnerability to alcohol use related to negative emotional states and past year stress and increased prevalence of psychiatric comorbidities related to negative affect observed in women.

3. Are there sex differences in neuroadaptations related to stress pathophysiology as a consequence of continued drinking? {#sec3}
==========================================================================================================================

3.1. Overview of stress-induced pathophysiology and the effects of alcohol {#sec3.1}
--------------------------------------------------------------------------

The interactions between pathophysiology related to stress and neuroadaptations induced as a result of AUD are complex and involve several brain and neurotransmitter systems. Stress-related changes in reward circuitry (e.g., mesocorticolimbic dopaminergic system) likely sensitize individuals to the reinforcing effects of substances of abuse ([@bib138]). Stress co-activates this reward circuitry simultaneously with brain stress systems, such as the hypothalamic-pituitary-adrenal (HPA) axis, and induces signaling through many neurotransmitters, including NE, CRF and dynorphin. Activation of these pathways likely enhances the effects of drugs of abuse on mood, craving and physiological reactivity, thus contributing to stress-related substance use ([@bib138]).

While a detailed review of stress pathophysiology and the effects of substance use on these systems is outside the scope of this review, the following sections focus on particular brain structures and neurotransmitters that may underlie the interactions between sex, stress, and alcohol. Specifically, the PFC, amygdala, and hippocampus as well as NE, CRF, dynorphin, and gamma-Aminobutyric acid (GABA) are identified as important structures and neurotransmitters implicated in stress-related alcohol use (see [Table 2](#tbl2){ref-type="table"} for a summary of findings on brain structures and neuromodulators underlying sex differences in stress-related alcohol use). For a comprehensive review of the neurobiology underlying the relationship between stress pathophysiology and addiction, see ([@bib108], [@bib109]; [@bib112]).Table 2Summary of the literature on brain structures and neuromodulators hypothesized to underlie sex differences in stress-related alcohol use.Table 2PreclinicalClinicalTranslation[e](#tbl2fne){ref-type="table-fn"}ReferencesBrain structures PFC[a](#tbl2fna){ref-type="table-fn"}Alcohol x stress???Alcohol x stress x sex?✓?[@bib74]; [@bib190] AmygdalaAlcohol x stress✓✓Yes[@bib47]; [@bib106]; [@bib113]; [@bib226]Alcohol x stress x sex??? HippocampusAlcohol x stress???Alcohol x stress x sex???Neurotransmitters NorepinephrineAlcohol x stress✓MixedYes[@bib106]; [@bib226]; [@bib86]; [@bib180]; [@bib117]; [@bib164]; [@bib150]; [@bib67]Alcohol x stress x sex✓??[@bib30] CRF[b](#tbl2fnb){ref-type="table-fn"}Alcohol x stress✓MixedMixed[@bib22]; [@bib102]; [@bib116]; [@bib235]Alcohol x stress x sex✓✓Yes[@bib113]; [@bib196] HPA axis[c](#tbl2fnc){ref-type="table-fn"}Alcohol x stress✓✓Yes[@bib30]; [@bib206]Alcohol x stress x sexMixed✓Mixed[@bib2]; [@bib6]; [@bib14]; [@bib30]; [@bib50]; [@bib153]Dynorphin/ kappaAlcohol x stress✓??[@bib10]; [@bib222]Alcohol x stress x sexMixed??[@bib31]; [@bib111]; [@bib148]; [@bib175]; [@bib234] GABA[d](#tbl2fnd){ref-type="table-fn"}Alcohol x stress✓??[@bib165]; [@bib187]Alcohol x stress x sex??? NeurodegenerationAlcohol x stress✓??[@bib223]; [@bib224]Alcohol x stress x sex???Hormones ProgesteroneAlcohol x stress✓??[@bib39]Alcohol x stress x sex✓??[@bib23]; [@bib39] EstrogenAlcohol x stress?✓?[@bib99]Alcohol x stress x sex???[^7][^8][^9][^10][^11][^12]

3.2. Brain structures {#sec3.2}
---------------------

### 3.2.1. PFC {#sec3.2.1}

The PFC-amygdala axis is critical for the processing of reward, inhibitory control, stress reactivity, and emotion regulation. Neuroimaging studies demonstrate that alcohol and stress induce alterations in PFC activity in both men and women ([@bib190]). For example, alcohol-related stimuli activated the medial PFC in abstinent individuals with AUD compared to healthy controls, and PFC activation was enhanced in those who subsequently relapsed to alcohol use ([@bib83]). Alcohol cues can also activate the dorsolateral PFC (dlPFC) in non-treatment-seeking individuals with AUD compared to social drinkers ([@bib72]). Regarding stress, HPA axis and autonomic responses to stress are enhanced following lesions to the ventromedial PFC ([@bib197]). The release of catecholamines, such as NE and DA, following stress significantly impairs PFC-dependent cognitive function ([@bib18]), whereas high levels of NE and DA in the amygdala and NAc strengthen habitual responding ([@bib17]).

Regarding sex differences, female rodents are more reactive to stress-induced PFC dysfunction than males, an effect mediated by high levels of estrogen ([@bib191]); thus, may account for the higher vulnerability to anxiety disorders in women. However, research on region-specific sex differences indicates that healthy social-drinking men show greater stress-related neural activation in the medial PFC compared to women ([@bib190]; [@bib74]). To our knowledge, there has not been any work examining sex differences in stress-induced PFC dysfunction as it relates to AUD. However, work by our group suggests that women smokers with smaller or blunted amphetamine-induced DA changes in the dlPFC were more likely to relapse to smoking following stress but not male smokers ([@bib232]). This finding suggests that stress may compromise the ability of the PFC to regulate inhibitory control, which in turn may be related to stress-induced drug use, particularly in women. As such, this work should be extended to examine sex differences in the PFC in individuals with AUD, especially considering recent evidence demonstrating sex differences in striatal cue-reactivity in problem drinkers; men showed stronger activation in response to alcohol cues than women in the striatum ([@bib100]).

### 3.2.2. Amygdala {#sec3.2.2}

The amygdala is a critical structure related to stress, arousal, and negative reinforcement. The bed nucleus of the stria terminalis (BNST; also referred to as the extended amygdala) is thought to comprise the brain stress systems, including the NE and CRF systems, that generate the negative affective states leading to compulsive drug-seeking (e.g., negative reinforcement) ([@bib106]). Negative affective stimuli increase amygdala activity partially through release of NE, leading to heightened arousal and attention, fear memory formation, and facilitated motor responses. NE release in response to stressors subsequently stimulates CRF release in the amygdala. Data from our group has demonstrated that reductions in NE signaling through alpha2-adrenergic receptors in the amygdala increases resilience to social stress, while decreasing anxiety- and depressive-like behaviors in mice ([@bib144]). CRF1 receptors are upregulated in the extended amygdala following a history of alcohol dependence ([@bib113]), and CRF1 antagonists administered directly into the amygdala reverse alcohol withdrawal-induced anxiety-like behavior in rodents ([@bib106]). Alcohol exposure enhances transmission of the inhibitory neurotransmitter GABA in the central amygdala of alcohol-dependent rodents, while increasing anxiety-like behavior and withdrawal-induced alcohol self-administration ([@bib47]); although, no data on sex differences in GABA signaling have been reported. Overall, increased weekly alcohol consumption has been associated with decreased right amygdala-orbital frontal cortex connectivity, as well as sensation-seeking; however no sex differences in amygdala functioning were explored ([@bib51]).

Regarding sex differences in the amygdala, imaging studies have demonstrated that men have larger amygdala volume ([@bib49]), men have larger amygdala activation in response to stress compared to women ([@bib190]), and there are sex-related differences in left and right amygdala activation in men and women recalling memories of negative emotional stimuli ([@bib38]). Thus, it has been hypothesized that women may drink more to achieve a desired reduction in negative affect or anxiety ([@bib110]). However, it should be noted that other studies suggest that men and women both show similar activation of the amygdala following negative stimuli ([@bib71]). Furthermore, excitatory signaling in the amygdala may be suppressed by alcohol to a greater degree in male rodents compared to females ([@bib127]), warranting additional research of sex differences regarding stress in the amygdala.

### 3.2.3. Hippocampus {#sec3.2.3}

The hippocampus is a key brain structure in the limbic system, which plays a key role in the formation of memories. Women may experience exacerbated cognitive deficits associated with drinking compared to men. Hippocampal damage after a binge alcohol paradigm is associated with spatial learning deficits in female but not male rodents ([@bib133]), and clinical studies demonstrate that women either with AUD or following alcohol administration have poorer performance on measures of working memory than men ([@bib68]; [@bib125]). Women who are heavy drinkers have greater impaired inhibition ([@bib225]; [@bib200]) and consistently perform more poorly on tasks involving spatial planning, problem solving and cognitive flexibility ([@bib68]; [@bib125]) when compared to men. Neuroimaging studies identify effects of AUD on activation in regions associated with spatial working memory in both men and women, but women with AUD differed from controls to a greater degree than men ([@bib154]). However, it is important to note that sex-dependent findings on the effects of AUD on cognitive function remain mixed ([@bib93]; [@bib215]) and warrant further investigation, especially because cognitive impairments have been linked to poorer treatment outcomes across most substance using-populations ([@bib201]).

3.3. Neurotransmitters & peptides {#sec3.3}
---------------------------------

### 3.3.1. Norepinephrine {#sec3.3.1}

Alcohol activates the noradrenergic system in both animals and humans ([@bib106]; [@bib135]; [@bib226]), and the noradrenergic system, in turn, plays a role in alcohol-related arousal, reinforcement, withdrawal, and stress reactivity ([@bib106]). Elevated plasma levels of epinephrine and NE have been documented in recently abstinent alcoholics ([@bib164]), and noradrenergic agents have been used to treat sympathetic hyperactivity during alcohol withdrawal ([@bib150]). Alcohol administration in rodents upregulates c-fos signaling, a marker of neuronal activity, in the locus coeruleus (LC), the nucleus containing noradrenergic cell bodies that projects to forebrain structures, including the amygdala ([@bib226]). Reductions in NE release occur by stimulation of inhibitory presynaptic alpha2 noradrenergic receptors or by blocking alpha1 or beta noradrenergic receptors.

Preclinical evidence suggests that increased NE signaling enhances stress-induced reinstatement to alcohol following extinction, whereas reduced noradrenergic activity, by blocking alpha1, alpha2a, or beta receptors, attenuates alcohol self-administration and stress-induced reinstatement to alcohol-seeking ([@bib86]). For example, the noradrenergic alpha-2 agonist guanfacine has been shown to reverse relapse vulnerability to alcohol-seeking in rats after social defeat-induced persistent stress (SDPS) ([@bib180]), an animal model of depression. Further, yohimbine, an alpha2-antagonist and pharmacologic stressor that increases noradrenergic activity, can reinstate alcohol-seeking in rodents ([@bib117]), and female rodents may be more sensitive to yohimbine-induced reinstatement to alcohol-seeking than males ([@bib30]). Indeed, electrophysiological studies confirm that female rodents have greater LC activation following hypotensive stress ([@bib52]), an effect that may be mediated by CRF. Probing the noradrenergic system with agents that perturb or attenuate noradrenergic activity to evaluate sex differences may help elucidate mechanisms underlying stress-precipitated drinking, but generally sex differences in the effect of NE on stress-related drinking have not been thoroughly examined.

In humans, noradrenergic agents have demonstrated efficacy in reducing drinking days per week, drinks per week, and stress- or cue-induced alcohol craving in individuals with AUD ([@bib86]); although, clinical trials of prazosin, an alpha1-adrenergic antagonist, for AUD with comorbid PTSD have produced mixed results ([@bib86]). To our knowledge, no studies have yet examined sex differences in treatment response for medications targeting the noradrenergic system for AUD in humans. Only two studies have evaluated sex differences in the effect of guanfacine on smoking and cocaine use outcomes. In daily cigarette smokers, our group has found that guanfacine preferentially reduced smoking lapse, cigarettes smoked, and tobacco craving following stress in women but not men ([@bib137]). Similarly, guanfacine decreased cocaine craving, alcohol craving, anxiety, and negative emotion following stress and drug imagery in cocaine-dependent women but not men ([@bib70]). The effect of guanfacine on stress-related drug self-administration and craving may be related to its ability to improve PFC connectivity during periods of stress ([@bib19]). Further, the sex-dependent differences in treatment response to guanfacine may be related to the ability of estrogen to regulate alpha2 receptors ([@bib142]) and facilitate the synthesis of NE in the LC in female vs. male rodents ([@bib210]). Overall, research is lacking in the examination of sex differences in noradrenergic mechanisms underlying stress-related alcohol use.

### 3.3.2. CRF {#sec3.3.2}

CRF regulates HPA axis reactivity, is a primary mediator of the stress response, and is hypothesized to play a key role in stress-related drug use, drug withdrawal, and relapse to drug-taking (for review see [@bib22]). CRF is a 41-amino acid polypeptide, and CRF-containing neurons are located throughout the brain, and particularly in regions important to stress pathophysiology (e.g., amygdala). CRF signals through two receptor subtypes, CRF~1~ and CRF~2~; however, the CRF~1~ receptor has been more extensively studied in addiction ([@bib107]). It is known that chronic alcohol exposure dysregulates CRF neurotransmission ([@bib22]). CRF administration reinstates alcohol-seeking in rodents ([@bib116]) and CRF~1~ receptor knockout mice exhibit reduced alcohol drinking ([@bib102]). CRF~1~ antagonists administered systemically or directly into the ventricles can reduce alcohol self-administration, attenuate yohimbine- and footshock-induced reinstatement of alcohol-seeking, and block withdrawal-induced anxiety-like behavior in alcohol-dependent animals ([@bib235]). However, the translation of these findings to humans is equivocal ([@bib113]), perhaps because sex differences have not been taken into account fully.

There are significant gaps in the literature regarding sex differences in CRF-mediated regulation of alcohol use in response to stress. Preclinical research has demonstrated that CRF-containing neurons are less able to adapt to high levels of CRF and LC sensitivity to CRF is greater in female vs. male rodents, suggesting that CRF-related dysfunction may contribute to the greater vulnerability to stress-related psychiatric disorders in women ([@bib20]). Indeed, alcohol withdrawal-induced CRF reactivity may be greater in female vs. male rodents ([@bib196]), but sex-dependent mechanisms underlying this difference are not well understood. Findings in anxious, alcohol-dependent women suggest that the CRF~1~ antagonist verucerfont reduced HPA axis reactivity to stress ([@bib113]; [@bib189]). Interestingly, estrogen is thought to regulate CRF gene expression and the CRF response to stress ([@bib214]; [@bib88]; [@bib158]; [@bib119]). For example, estrogen replacement therapy may moderate the CRF response to emotional stress in postmenopausal women ([@bib124]). However, work in this area remains limited.

Sex-dependent effects of stress and alcohol on CRF regulation of the HPA axis have also been understudied, but a picture is emerging. Preclinically, corticosterone exposure during adolescence may sensitize animals to stress-induced responding for alcohol later in life and corticosterone-treated adolescent female rodents were more sensitive to yohimbine-induced reinstatement of alcohol-seeking than males in adulthood ([@bib30]). Similarly, in human subjects exposure to early life stress, including childhood trauma or maltreatment, is related to heightened stress reactivity, increased depressive symptomology ([@bib89]), and higher adrenocorticotropic hormone (ACTH) levels in response to CRF administration as adults ([@bib90]).

Acute alcohol consumption can also increase plasma corticosterone and cortisol levels in both rodents and humans, respectively, in a sex-dependent manner. For example, while heavy drinkers have demonstrated increases in plasma cortisol following acute alcohol intake ([@bib206]), one study found that regardless of alcohol dependence history, women demonstrated a more robust response of ACTH and cortisol following the neuroendocrine stimulation test (peripherally-acting dexamethasone/CRF) than men ([@bib14]). Other studies have demonstrated that the cortisol awakening response was higher in heavy drinking women than moderate drinking women following chronic consumption ([@bib2]). In contrast, separate studies of recently abstinent (up to 4 weeks) alcohol-dependent men ([@bib26]; [@bib128]; [@bib62]) and women ([@bib25]) or social drinkers with a family history of alcoholism ([@bib204]) indicate a blunted cortisol response to stress (e.g., public speaking, mental arithmetic) compared to healthy controls; although, direct comparison of sex differences in stress reactivity was not conducted in these studies due to small sample size.

In preclinical work, female rodents exhibited greater ACTH and corticosterone responses following alcohol and stress exposure compared to males ([@bib30]; [@bib50]). Female mice deficient in the endogenous opioid peptide β-endorphin, a regulator of the HPA axis, also demonstrated increases in voluntary binge-like alcohol intake compared to wild-type controls, an effect not present in males ([@bib153]). In the same study, females deficient in β-endorphin exhibited increased baseline anxiety, corticosterone, and CRF mRNA in the extended amygdala, all of which normalized following alcohol consumption ([@bib153]). However, other studies indicate that male rodents exhibited greater withdrawal-induced elevations in plasma corticosterone relative to females ([@bib6]). While the literature is mixed both among and between preclinical and clinical findings, it is likely that chronic alcohol consumption produces profound alterations in HPA axis reactivity. The discrepancy in findings related to sex differences may be associated with study timeframe (e.g., early HPA dysregulation in acute alcohol use vs. the withdrawal period of rodents and recently abstinent individuals with AUD).

Overall, the data suggest that females may be more sensitive to alterations in CRF and HPA axis reactivity induced by stress and continued alcohol use compared to males. Females may also be more sensitive to withdrawal-induced changes in CRF activity, whereas males may exhibit a heightened corticosterone response following withdrawal. Research is needed to extend and reproduce these preliminary findings as there is promise in using these interconnected systems as probes to understand mechanisms underlying drinking to regulate negative affect and stress reactivity.

### 3.3.3. Dynorphin/kappa {#sec3.3.3}

The dynorphin/kappa opioid receptor (KOR) system has also been implicated in the stress response and addiction ([@bib10]) but studies examining sex differences in the role of the dynorphin/KOR system on alcohol intake have shown mixed results. Dynorphin, an endogenous opioid peptide, binds exclusively to the KOR and is released in response to stress. KOR activation by dynorphin is associated with stress-related behaviors in rodents and humans ([@bib139]), and may contribute to negative affective states associated with drug withdrawal ([@bib175]). Indeed, KOR antagonists have demonstrated efficacy in reducing anxiety- and depressive-like behavior in studies using only male rodents ([@bib139]). In rodents, KORs may also be dysregulated following chronic alcohol exposure (e.g., 4-week intermittent vapor exposure \[14 h on/10 h off\]), consequently leading to an increase in alcohol self-administration ([@bib222]). The KOR antagonists JDTic and nor-binaltorphimine (nor-BNI) have been shown to attenuate alcohol self-administration, cue-induced reinstatement of alcohol-seeking, and alcohol-induced conditioned place preference (CPP) in rodents ([@bib10]; [@bib175]; [@bib222]), although this effect is dependent on rodent strain. It should be noted that nor-BNI may only be effective in alcohol-dependent vs. non-dependent animals ([@bib222]), and most of the aforementioned studies were conducted in males only.

Sex differences in the dynorphin/KOR system have been studied for pain, mood dysregulation, and responses to drugs of abuse ([@bib176]). For example, in non-human primates, females are less sensitive to the analgesic effect of KOR agonists ([@bib152]). Female rats are less sensitive to the depressive-like effect of a KOR agonist than males ([@bib183]), possibly indicative of an enhanced role for KORs in anxiety- and depressive-like states in male rodents. Regarding alcohol, pharmacologic studies suggest that nor-BNI reduces alcohol intake in female rodents, but increases alcohol intake in male rats following social isolation stress ([@bib148]). However, other studies have found that nor-BNI decreased drinking in male rodents, with no effect in females ([@bib234]).

Sex dependent effects on alcohol-motivated behavior in mice with genetic manipulations of KOR have also been variable. In one study, female prodynorphin knockout mice exhibited reduced alcohol preference ([@bib31]), but others have shown that female prodynorphin knockouts exhibit increased alcohol intake ([@bib175]), likely because different mouse strains were used in these studies. Both female and male KOR knockout mice also exhibit reduced alcohol consumption, however ([@bib111]). Overall, results are mixed with regard to sex-related differences in the role of the dynorphin/KOR system on alcohol-motivated behavior. While changes in science (e.g., NIH) policy ([@bib46]) ensure that female rodents are included in studies probing the dynorphin/kappa system for stress-related drinking behavior, current research in this area is lacking.

### 3.3.4. GABA {#sec3.3.4}

One of the primary molecular targets for alcohol is the family of GABA~A~ receptors, which are required for its acute sedative effects ([@bib53]). Imaging studies show that cortical GABA levels are higher in women compared to men ([@bib186]). Our group has also shown that women have greater GABA~A~-benzodiazepine receptor availability than men ([@bib63]). Similar observations have been made in animal models ([@bib205]). GABA acts tonically in the amygdala at GABA~A~ receptors to blunt anxiety-like responses, as does acute alcohol ([@bib187]), and chronic alcohol exposure, by way of chronic intermittent ethanol (CIE), induces GABA~A~ receptor plasticity in the amygdala ([@bib123]). Female mice also have more high affinity GABA binding sites than males, and these sites are more sensitive to stress-induced dysregulation in females than in males ([@bib198]). Together, these results suggest that decreasing GABA transmission could have more profound effects in women than in men.

As discussed above, another effect of chronic alcohol use is NE hyperexcitability ([@bib67]), leading to greater stress reactivity and anxiety. This hyperarousal could be enhanced if GABA neurons are inhibited. NE can also activate GABAergic neurons in the amygdala, which could counteract the stimulatory effects of NE on principal neurons. However, chronically elevated NE signaling induced by long-term alcohol use can desensitize β-adrenergic receptors on GABA neurons of the amygdala (for review see ([@bib165])). This allostatic imbalance, a disruption in the adaptive processes that sustain homeostasis of the stress response ([@bib136]), is likely to promote stress and anxiety-like behaviors. Thus, chronic alcohol use may increase the susceptibility to stress-induced behaviors and promote relapse to alcohol drinking by inducing NE hyperstimulation and decreasing amygdala GABA signaling. The increased GABA receptor number in the female brain may also contribute to the more pronounced effects in female mice ([@bib198]).

3.4. Alcohol-induced neurodegeneration and relationship to stress and drinking {#sec3.4}
------------------------------------------------------------------------------

While markers of peripheral inflammation have long been associated with a variety of psychiatric disorders, including AUD ([@bib209]; [@bib76]), the role that neuroinflammation plays has only recently been examined ([@bib92]; [@bib101]). Microglia, the resident macrophages of the brain, are involved in a variety of physiologic and pathologic processes, most notably in the initiation and maintenance of neuroinflammation. Resting microglia are tightly regulated by interactions with neurons, and microglia normally protect neurons ([@bib173]). For example, when provided with signals that indicate the presence of tissue damage or pathogens, microglia become activated and carry out repair functions. However, excessive activation leads to the release of substances that cause neuronal dysfunction and death, such as inflammatory cytokines, chemokines, reactive oxygen species, nitric oxide, and glutamate ([@bib229]; [@bib216]; [@bib140]; [@bib32]), and through these pathways may contribute to alcohol-induced neurodegeneration. It is now generally accepted that alcohol initially activates microglia ([@bib134]), which plays a role in alcohol-induced adaptations in the brain; but more recent neuroimaging studies suggest that with chronic alcohol consumption (e.g., alcohol-dependent subjects imaged 1--4 days after their last drink but before the occurrence of major brain changes following abstinence ([@bib92]) or recently detoxified alcohol-dependent subjects within 1 month of medically assisted withdrawal ([@bib101])) the neuroimmune and peripheral immune systems become suppressed ([@bib92]; [@bib101]).

Women are more susceptible to alcohol-related impaired peripheral immunity than men, including alcohol-induced liver disease ([@bib179]), cardiac myopathy ([@bib145]), and hypertension ([@bib36]). In the brain, it has long been thought that women with AUD have more brain atrophy, including gray and white matter volume loss, than do men with AUD ([@bib172]; [@bib95]; [@bib202]), although some findings are conflicting ([@bib170], [@bib171]). Markers of neurodegeneration, including neuroimmune function, have been linked to decrements in executive function ([@bib68]; [@bib125]) and poor AUD treatment response ([@bib73]; [@bib56]; [@bib155]). Taken together, these observations suggest that women may be more susceptible to the neuroimmune consequences of alcohol than men, which has critical behavioral and cognitive implications.

In addition to neuroimmune function, synaptic density may be a marker of neurodegeneration. Preclinical studies have shown that synaptic density was lower in rodents chronically exposed to alcohol vs. control animals in cerebellar Purkinje cells ([@bib54]) and cerebellar cortex ([@bib55]). In a subset of chronically alcohol-treated animals that recovered for 20 weeks, there was an apparent restoration of synaptic density to control levels ([@bib54]). Additionally, lower synaptic density may contribute to neuronal instability ([@bib65]), particularly a glutamate-GABA imbalance, which is known to develop with chronic alcohol consumption ([@bib221]).

There is also evidence to suggest that neurodegeneration alters the stress response, and possibly the effect of stress on alcohol consumption. A critical role of microglia is to support and protect neurons, to prune dendritic spines, and to promote synapse formation. Stress perturbates this homeostatic balance. For example, preclinical studies demonstrate that stress induces changes in the shape and molecular makeup of microglia ([@bib181]) and causes synaptic loss on neurons in the PFC ([@bib162]) and hippocampus ([@bib141]), which were associated with depressive behaviors. More recently, stress-induced activation of microglia was shown to contribute directly to neuronal "remodeling" and synaptic deficits in the PFC, which underlie symptoms of anxiety and depression ([@bib228]). Finally, sensitization of stress-induced microglial activation has been observed following alcohol exposure ([@bib223]; [@bib224]). However, to our knowledge, sex differences in the role of stress on alcohol-induced neurodegeneration have not been well-characterized. Because women may be more susceptible to the neuroimmune consequences of alcohol than men, probing systems that may rescue dendritic spine loss and protect against alcohol and stress-induced changes in synaptic density, including the noradrenergic and GABA systems, may be a critical step in translational research for identifying markers of neurodegeneration and sex-appropriate treatment development.

4. How are sex hormones related to stress and drinking? {#sec4}
=======================================================

Alterations in sex steroid levels, associated with the hypothalamic pituitary gonadal (HPG) axis, have effects on various neurotransmitter systems, including brain stress systems. For instance, progesterone and its metabolites allopregnanolone and pregnanolone regulate neuronal function, particularly through non-genomic action of GABA~A~ receptors ([@bib84]; [@bib129]). The relationship between sex hormones and GABA~A~ receptors likely contribute to the anxiolytic effects of alcohol; namely because the anxiolytic effects of alcohol have been attributed to GABA~A~ receptor function ([@bib126]). Progesterone and its metabolites also interact with other neurotransmitter systems, including the glutamate and nicotinic acetylcholine receptor systems (α4β2, α5; for review see ([@bib129]; [@bib212])), which likely modulate the effect of alcohol on the brain. Additionally, serotonin may mediate various physiological actions of estrogen, as estradiol alters the concentration of serotonin ([@bib184]). Estrogens, including estradiol, have been implicated as mediators of DA efflux in women but not men, likely affecting motivation for rewards such as drugs of abuse ([@bib230]). Finally, there is initial evidence that estrogen may up-regulate α~2~A-adrenergic receptors, which would likely impact stress reactivity and substance use ([@bib167]) due to perturbations in NE signaling.

Increasing evidence suggests that ovarian hormones may account for sex differences in alcohol self-administration, alcohol withdrawal, and reinstatement to alcohol-seeking in rodents and humans ([@bib39]; [@bib11]). Women with consistently high estradiol levels also have higher alcohol intake than those characterized by lower estradiol levels ([@bib149]). Similarly, chronic estradiol replacement can increase alcohol drinking in female rodents, whereas chronic testosterone can decrease drinking in male rodents ([@bib29]). Increases in progesterone and allopregnanolone have been associated with decreased alcohol withdrawal severity, with female rodents exhibiting more sensitivity to the anxiolytic-like effect of allopregnanolone during withdrawal ([@bib23]; [@bib39]).

These results are consistent with evidence that drinking behavior, including intake, fluctuates over the course of the menstrual or estrus cycles, when sex steroids are also in flux ([@bib23]). Phases of the estrus and menstrual cycles are characterized by higher levels of estradiol associated with higher risk of drinking and binge drinking ([@bib131]; [@bib23]). Among women in the early follicular menstrual phase (days 1--5; characterized by low levels of ovarian hormones), drinking to cope with negative affect predicted increased alcohol consumption ([@bib99]). These results should be viewed with caution as there are methodological variations associated with dichotomizing the cycles (see review ([@bib7])), making it difficult to determine the influence of ovarian hormones on alcohol consumption in these studies.

5. Reducing stress and negative affect as a treatment target for AUD {#sec5}
====================================================================

5.1. Pharmacological {#sec5.1}
--------------------

Abstinence from alcohol or reduction of high-risk drinking can prevent and reduce many of the harmful health consequences of drinking. Successful treatment of AUD is associated with lower blood pressure, improved liver function, and stabilization of many conditions, including, cardiomyopathy, gastritis, ascites, and edema ([@bib207]). There are three FDA-approved medications for AUD; disulfiram, naltrexone (oral and depot formulations), and acamprosate, each with limitations regarding their efficacy and use. Research on disulfiram has been primarily conducted in males, and there is insufficient data to determine if there are sex differences in treatment response ([@bib4]). Post-hoc evaluation of sex differences in medication response to naltrexone and acamprosate suggests that they may be equally effective for women ([@bib4]; [@bib231]; [@bib78]). However, in a large U.S.-based study, effect sizes for % days abstinent for acamprosate (effect size = 0.04) and naltrexone (effect size = 0.22) were small to moderate ([@bib15]), and lack of sex differences may simply represent a floor effect.

As reviewed above, NE, CRF, dynorphin/KOR, and GABA all play a role in stress pathophysiology and associated alcohol consumption. Medications targeted to each system have been successful in reducing alcohol-motivated behavior, including alcohol craving, alcohol-seeking and consumption, and stress-induced alcohol relapse. While research on sex differences in each of these systems has been limited, there is some indication that targeting brain stress systems for sex-appropriate pharmacotherapeutic treatment options holds promise. Preliminary work suggests that noradrenergic agents may preferentially reduce stress-related drug outcomes in women compared to men. For example, in daily smokers, guanfacine attenuated cigarettes smoked and tobacco craving following stress in women ([@bib137]). Similarly, guanfacine reduced alcohol craving, cocaine craving, anxiety, and negative emotion following stress in cocaine-dependent women but not men ([@bib70]). However, sex difference research in humans with AUD is limited.

Research with CRF antagonists is mixed but some data suggest that they are efficacious in reducing HPA axis reactivity following stress in women with AUD ([@bib189]). KOR antagonists also show promise, as preclinical data demonstrate that these agents preferentially reduce alcohol self-administration in female rodents compared to males ([@bib148]). Because GABA binding sites are more sensitive to stress-induced dysregulation in female rodents ([@bib198]), GABAergic agents may also be a promising target for problematic alcohol use, particularly in women drinking for negative reinforcement. Medications targeting neuroinflammation and neurodegeneration are a growing interest in addiction ([@bib178]). Women appear to be more susceptible to the neuroimmune consequences of alcohol than men, with stress and stress-related drinking likely playing a critical role in this relationship. Examining sex-dependent treatment response to medications which target neuroinflammation or neurodegeneration is a promising line of inquiry.

Overall, sex difference research in treatment efficacy for agents targeting each of these stress systems is limited in both rodent models of high alcohol drinking and in humans with AUD. The considerable body of data suggesting that women are more likely to drink to regulate negative affect and stress, while men are more likely to drink for the reinforcing properties of alcohol, indicates an important direction in the development of sex-appropriate treatments for AUD. Given the involvement of the NE, CRF, dynorphin/KOR, GABA, and neuroinflammation systems in stress pathophysiology and addiction, targeting these systems to attenuate sex-dependent mechanisms that maintain drinking is critical.

5.2. Behavioral measures related to AUD {#sec5.2}
---------------------------------------

### 5.2.1. Heart rate variability (HRV) {#sec5.2.1}

HRV, changes in time between beat-to-beat intervals, is thought to reflect vagal reactivity and autonomic nervous system flexibility ([@bib27]). Emerging evidence suggests that HRV may be a potential mechanism underlying the relationship between stress and substance use. A recent meta-analysis found that reductions in tonic HRV are associated with psychiatric disorders, including anxiety and depression, whereas elevations in tonic HRV are reflective of healthier states ([@bib28]; [@bib40]). For example, individuals with higher tonic HRV were better able to adapt to stress ([@bib163]). Women have greater vagal mediation of heart rate, autonomic balance at rest, and vagal withdrawal in response to stress compared to men ([@bib121]; [@bib120]). Thus, HRV biofeedback may have clinical benefits for women seeking non-pharmacological treatment for AUD. HRV has been shown to predict alcohol craving ([@bib174]) and is reduced by heavy alcohol consumption. Women experience dysregulated HRV in response to alcohol, less suppression of HRV in alcohol challenges and have greater increases in HRV in response to visual cues, including alcohol cues ([@bib21]; [@bib213]). Consistent with these findings, HRV biofeedback has been shown to improve alcohol abstinence outcomes at 1-year follow-up ([@bib168]) and has recently gained support as an adjunctive therapy for depression ([@bib69]). While support for HRV as a mechanism underlying negative affect and substance use is relatively new, HRV may be dysregulated during alcohol exposure and HRV-based interventions may improve AUD treatment outcomes, especially among women drinkers.

### 5.2.2. Psychosocial interventions {#sec5.2.2}

To date, several psychosocial interventions, including Cognitive Behavioral Therapy (CBT), 12-Step Facilitation/Alcoholics Anonymous (TSF/AA), Contingency Management (CM), and Motivational Interviewing (MI)-Based Interventions have proven to be effective treatments for AUD ([@bib80]; [@bib81]; [@bib169]). CBT has also been shown to effectively treat comorbid AUD and depressive/anxiety symptomatology ([@bib161]). However, limited research has focused on sex differences in behavioral treatments as they relate to reductions in alcohol consumption and stress reactivity.

Two recent studies used female-specific CBT, including modules to target social support, interpersonal functioning, and coping with negative affect/anxiety, to treat women with AUD ([@bib59], [@bib60]); although, when compared to sex-neutral treatment, both treatments showed similar positive outcomes ([@bib60]). Another study has demonstrated that women were more likely to participate in AA, have better alcohol-related outcomes, and show decreases in depressive symptoms and drinking to cope/reduce tension ([@bib147]). It should be noted that Project MATCH results demonstrated equivalent, modest response rates to CBT, TSF/AA, and MI-based interventions ([@bib80]; [@bib81]) across sexes; however, research regarding the overall effectiveness of these interventions for women remains understudied and requires more sophisticated methodologies ([@bib79]), with Project Match including 70--80% men in their treatment populations ([@bib80]; [@bib81]). Additionally, research has demonstrated that CM is equally beneficial for both sexes, although its use is often limited due to financial resources ([@bib177]). Thus, additional research is needed to improve treatment outcomes for women receiving psychosocial interventions. Specifically, it is imperative that future studies include more advanced methodologies, as well as enough women in sample sizes to adequately explore sex-related factors that may mediate or moderate treatment outcomes and thus elucidate underlying mechanisms between men and women with AUD or problematic drinking ([@bib79]). Based upon the current evidence, it appears that concurrently targeting stress reactivity, as well as alcohol use, would serve to improve treatment outcomes; however more targeted research on sex differences is needed.

### 5.2.3. Mindfulness-based interventions (MBIs) {#sec5.2.3}

There is growing evidence that MBIs are associated with reductions in negative affect and anxiety ([@bib94]), as well as support for its use to treat a variety of substance use disorders (SUDs [@bib233]). Mindfulness-based relapse prevention (MBRP) has shown particular promise in the treatment of SUDs, including AUD. For instance, participants receiving MBRP- or CBT-based relapse prevention (RP), both showed a lower risk of relapse to heavy drinking at 6-month follow-up; however, MBRP demonstrated significant decreases in heavy drinking compared to CBT-based RP or treatment as usual at 12-month follow-up ([@bib33]). When tailored to women substance users with a history of trauma, those attending more sessions of MBRP showed greater reductions in alcohol addiction severity and perceived stress, although it should be noted that these results were preliminary ([@bib8]). Overall, there appears to be promise in the utility of MBIs among women to decrease alcohol consumption and perceived stress.

6. Conclusions {#sec6}
==============

The present evidence suggests that sex difference research (SABV) and treatment development is needed to address the growing rates of alcohol use and AUD as well as the exacerbated alcohol-related health consequences among women. Current FDA-approved medications for AUD have not yet been adequately studied across sexes and likely do not directly address the factors contributing to the onset and maintenance of alcohol use in women. Overall, women are generally more likely to drink to regulate negative affect and stress reactivity (i.e., negative reinforcement) while men may be more likely to drink for positive reinforcement (see [Fig. 1](#fig1){ref-type="fig"}). Drinking motivated by negative or positive reinforcement differs in its neurobiological underpinnings, and probing stress pathophysiology may be an important direction to develop tailored treatments for women. Sex differences in onset and maintenance of alcohol use begin to develop during adolescence, coinciding with exposure to early life stress and emerging developmental changes, including differences in brain morphology. These factors continue to affect alcohol use into adulthood, when reduced responsivity to stress, increased affect-related psychiatric comorbidities and alcohol-induced neurodegeneration contribute to chronic and problematic alcohol use, particularly for women.Fig. 1Schematic summarizing findings from the present review that the general population of women is more likely to drink for negative reinforcement (e.g., stress and negative affect), and the general population of men is more likely to drink for positive reinforcement (e.g., stimulation), which reflects sex differences in the neurobiological underpinnings of drinking behavior. However, as also indicated in [Fig. 1](#fig1){ref-type="fig"}, these populations overlap, and some women may drink primarily for positive reinforcement and some men may drink primarily for negative reinforcement. This line of evidence suggests that probing stress pathophysiology may be an important direction to develop tailored treatments for women.Fig. 1

Sex-dependent interventions targeting stress pathophysiology are likely an important direction in AUD treatment development for women, as these systems and structures underlie and maintain alcohol consumption in women. Probing the brain stress systems, such as the noradrenergic system, and its associated brain regions may be relevant for examining sex differences in stress responses and chronic alcohol use. For example, noradrenergic agents, such as yohimbine, may be utilized to probe stress-induced PFC dysfunction in preclinical samples, and decreasing NE with noradrenergic targets may attenuate stress reactivity and associated effects on PFC function among individuals with AUD. In fact, preliminary work highlighted in this review suggests that noradrenergic agents may preferentially reduce smoking self-administration and craving following stress in women; however, surprisingly little work has extended these findings to AUD. It should be noted that the impact of comorbid drug use (e.g., cigarette smoking, cocaine use) and AUD on stress pathophysiology and brain neuroadaptations was not discussed in this review and adds to the complex findings documented across human studies. Future research should build on the findings presented on sex differences in stress-related alcohol use and examine how relationships between sex and stress may be impacted by polysubstance use. There is growing evidence across other substances of abuse that women use drug and non-drug reinforcers (e.g., food) for stress and affect regulation ([@bib137]; [@bib219]; [@bib211]; [@bib114]).

Additional evidence demonstrates that targeting other brain stress systems may also be promising targets for sex-appropriate pharmacological treatment development for AUD. Preliminary data suggests that CRF antagonists may reduce HPA-axis reactivity following stress among women with AUD and KOR antagonists have been shown to reduce alcohol self-administration in female rodents, illustrating the promise of pharmacological developments targeting these systems. Similarly, GABAergic agents may be a promising avenue for treatment development for women with AUD, as women have higher cortical GABA levels; thus, these agents may reduce problematic alcohol use among those drinking for negative reinforcement. Because evidence suggests that women may be more susceptible to the neuroimmune consequences of alcohol than men, future research with agents such as glial modulators to target neuroinflammation or probing systems that protect against alcohol or stress-induced alterations in synaptic density may be an important next step in SABV and alcohol research. Finally, emerging psychosocial and behavioral interventions, including HRV and MBIs, may be beneficial in the treatment of AUD in women by targeting relevant stress pathophysiology.

Overall, further research is warranted to elucidate sex differences in brain systems and regions that underlie mechanisms associated with alcohol consumption and relapse among women, with particular emphasis on modulating stress reactivity in women (e.g., PFC-amygdala axis; brain stress systems); [Table 2](#tbl2){ref-type="table"} highlights that much of this work has yet to be completed. This line of investigation will result in the development of treatments to target these sex-dependent systems to attenuate mechanisms that maintain drinking in women.
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[^1]: Dual first authorship.

[^2]: SDPS = social defeat-induced persistent stress.

[^3]: PTSD = post-traumatic stress disorder.

[^4]: CRF = corticotropin-releasing factor.

[^5]: IAPS = International Affective Picture System.

[^6]:  = also used in clinical paradigms; self-report questionnaires/measures are not described above.

[^7]: Legend: ? = unknown, not been studied; ✓ = studied with positive findings; mixed = mixed findings.

[^8]: PFC = prefrontal cortex.

[^9]: CRF = corticotropin-releasing factor.

[^10]: HPA = hypothalamic-pituitary-adrenal.

[^11]: GABA = gamma-Aminobutyric acid.

[^12]: Correspondence of findings between preclinical and clinical.
